AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 241 min read$IBO

DSS, INC. sold $2K of IBO

DSS, INC. sold 906 shares of IMPACT BIOMEDICAL INC. (IBO) at an average of $1.86 ($0.55–$7.06) across 3 trades over 2026-09-22 to 2026-09-24.

Original reporting
SEC EDGAR · DSS, INC.
Published Sep 24, 2026, 11:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 12:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IBO
Neutral
high confidence
Mentioned
$IBO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IBONeutralLow
01

Why it matters

The sale represents a routine liquidity move; no material change to ownership.

02

Market read

Minor insider transaction with limited trading relevance.

03

What to watch

Potential upcoming clinical data could affect future insider activity.

Relevance 3/10Novelty 4/10Timing: filing 2026-09-24

Background

Form 4 filings disclose insider trades; DSS, Inc. is a 10% owner of IBO.

Company-level read

Ticker impact

$IBONeutralHigh confidence
Context

SEC Form 4 shows DSS, Inc. sold 906 shares of Impact Biomedical (IBO) for $1,686 total.

Expected impact

No significant impact expected.

Evidence & confidence

The transaction size is tiny relative to market cap and shares held remain large.

Market effects

Sector

None; isolated insider transaction.

Regional

None; company is US‑listed biotech.

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal concerns, but size is negligible.

Key entities

  • company
    Impact Biomedical Inc.

    US‑listed biotech (ticker IBO).

  • insider
    DSS, Inc.

    10% owner filing the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IBO insider trading history →

Related articles

NOV 3
$DSSMed

DSS, Inc. Announces SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination

DSS, Inc. (DSS) announced the SEC declared effective the Form F-4 registration statement for its business combination with Impact Biomedical (IBO) and Zoar Limited. The combined company, Zoar Limited, is expected to trade on NYSE American under the ticker 'ZOAR,' pending approval. Impact stockholders will vote on the merger on November 13, 2026. The transaction remains subject to regulatory and shareholder approvals.

finanznachrichten.de2 min
NOV 3
$IBOMed

Impact Biomedical, Inc.: Impact Biomedical Inc. and Zoar Limited Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination

Impact Biomedical (IBO) and Zoar Limited announced the SEC's approval of their Form F-4 registration statement for a business combination. The deal, pending shareholder and NYSE American approval, will result in a combined company operating as Zoar Limited (ZOAR). A special meeting for Impact stockholders is scheduled for November 13, 2026, to vote on the proposal.

finanznachrichten.de2 min
NOV 3
$IBOMed

Shareholders are set to vote Nov. 13 on a proposed combination. The SEC declared the deal paperwork effective.

DSS, Inc. (NYSE American:DSS) and Impact Biomedical Inc. (NYSE American:IBO) announced the SEC declared effective the registration statement for their business combination with Zoar Limited. The deal, pending shareholder approval and other conditions, aims to create a pharmaceutical company focused on active pharmaceutical ingredients. Impact's stockholders will vote on November 13, 2026.

stocktitan.net2 min
SEP 16
$IBOMed

Impact BioMedical, Inc.: Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley's Limited)

Impact Biomedical Inc. (IBO) filed a Form F-4 registration statement with the SEC for its proposed merger with Zoar Ltd. The merger, subject to regulatory and shareholder approvals, aims to create a pharmaceutical company focused on active pharmaceutical ingredients. The completion depends on SEC approval, shareholder votes, and NYSE American listing.

finanznachrichten.de2 min
NOV 3
$ASPEMedAI 8/10

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $18.0M of ASPE (indirect holdings)

ARCH Venture Fund X, L.P. purchased 1,200,000 indirectly-held shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($18.00M total) on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).

SEC EDGAR1 min
NOV 3
$ASPELow

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $2.0M of ASPE

ARCH Venture Fund X, L.P. purchased 133,333 shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($2.00M total) across 2 trades on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).

SEC EDGAR1 min